EFFECTS OF PIOLITAZONE ON SPUTUM BIOMARKERS OF INFLAMMATION AND LUNG EPITHELI

吡奥利他酮对炎症和肺上皮痰生物标志物的影响

• 批准号: 7982137
• 负责人: PAUL BERINGER
• 金额: $ 3.25万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982137
• 关键词: 2,4-thiazolidinedione; Biological Markers; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Gelatinase B; Grant; Institution; Lung Inflammation; Modeling; Phase II Clinical Trials; Pioglitazone; Research; Research Personnel; Resources; Source; Sputum; Thiazolidinediones; United States National Institutes of Health; cystic fibrosis patients

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In this study we intend to assess the effect of the PPARy-activating thiazolidinedione pioglitazone on sputum MMP-9 levels in patients with Cystic Fibrosis. A PK/PD model will be developed to determine the optimal dose for phase II studies

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 在这项研究中，我们打算评估 PPARγ 激活噻唑烷二酮吡格列酮对囊性纤维化患者痰 MMP-9 水平的影响。将开发 PK/PD 模型以确定 II 期研究的最佳剂量